Vedere Bio, Inc.
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
- Kevin Bitterman, PhD Chairman of the Board
- Cyrus D. Mozayeni Founder and CEO
- Eileen McCullough SVP, Operations and Corporate Strategy
- Karen Guerin, PhD Director of Virology